To further validate the IGF1R signaling in PSPC1-potentiated cell motility, we treated the PSPC1-overexpressing HCC cells with IGF1R specific inhibitor cyclolignan picropodophyllin (PPP) a potent inhibitor blocked its expression and activity without affecting other insulin family receptors [33,34]. This evidence concerns the gene IGF1R and hepatocellular carcinoma.